ArticleBMC cancer2010
Integration of transcript expression, copy number and LOH analysis of infiltrating ductal carcinoma of the breast.
Article in BMC cancer, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- Gene Expression Meta-Analysis of Potential Metastatic Breast Cancer Markers.Current molecular medicine · 2017Pooled it
- Integrated analysis of copy number variation and genome-wide expression profiling in colorectal cancer tissues.PloS one · 2014Trial
- Gene co-expression network based on part mutual information for gene-to-gene relationship and gene-cancer correlation analysis.BMC bioinformatics · 2022Article
- Aberrations of Chromosomes 1 and 16 in Breast Cancer: A Framework for Cooperation of Transcriptionally Dysregulated Genes.Cancers · 2021Article
- High Expression of PAMR1 Predicts Favorable Prognosis and Inhibits Proliferation, Invasion, and Migration in Cervical Cancer.Frontiers in oncology · 2021Article
- Article
- Correlation between minimum apparent diffusion coefficient values and the histological grade of breast invasive ductal carcinoma.Oncology letters · 2018Article
- RNA Interference of IQ Motif Containing GTPase-Activating Protein 3 (IQGAP3) Inhibits Cell Proliferation and Invasion in Breast Carcinoma Cells.Oncology research · 2016Article
- Extensive Transcriptomic and Genomic Analysis Provides New Insights about Luminal Breast Cancers.PloS one · 2016Article
- Expression and diagnostic value of CCT3 and IQGAP3 in hepatocellular carcinoma.Cancer cell international · 2016Article
- Genomic-Wide Analysis with Microarrays in Human Oncology.Microarrays (Basel, Switzerland) · 2015Review
- The Deleted in Liver Cancer 1 (Dlc1) tumor suppressor is haploinsufficient for mammary gland development and epithelial cell polarity.BMC cancer · 2015Article
- Article
- Similarity of markers identified from cancer gene expression studies: observations from GEO.Briefings in bioinformatics · 2014Article
- Longitudinal study of recurrent metastatic melanoma cell lines underscores the individuality of cancer biology.The Journal of investigative dermatology · 2014Article
- IQGAP3 promotes EGFR-ERK signaling and the growth and metastasis of lung cancer cells.PloS one · 2014Article
- Analysis of genetic aberrations on chromosomal region 8q21-24 identifies E2F5 as an oncogene with copy number gain in prostate cancer.Medical oncology (Northwood, London, England) · 2013Article
- Fine map of the Gct1 spontaneous ovarian granulosa cell tumor locus.Mammalian genome : official journal of the International Mammalian Genome Society · 2013Article
- MicroRNAs and Recent Insights into Pediatric Ovarian Cancers.Frontiers in oncology · 2013Article
- Quantitative proteomic analysis in metastatic renal cell carcinoma reveals a unique set of proteins with potential prognostic significance.Molecular & cellular proteomics : MCP · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA major challenge in the interpretation of genomic profiling data generated from breast cancer samples is the identification of driver genes as distinct from bystander genes which do not impact tumorigenesis. One way to assess the relative importance of alterations in the transcriptome profile is to combine parallel analyses that assess changes in the copy number alterations (CNAs). This integrated analysis permits the identification of genes with altered expression that map within specific chromosomal regions which demonstrate copy number alterations, providing a mechanistic approach to identify the 'driver genes'.
methodsWe have performed whole genome analysis of CNAs using the Affymetrix 250K Mapping array on 22 infiltrating ductal carcinoma samples (IDCs). Analysis of transcript expression alterations was performed using the Affymetrix U133 Plus2.0 array on 16 IDC samples. Fourteen IDC samples were analyzed using both platforms and the data integrated. We also incorporated data from loss of heterozygosity (LOH) analysis to identify genes showing altered expression in LOH regions.
resultsCommon chromosome gains and amplifications were identified at 1q21.3, 6p21.3, 7p11.2-p12.1, 8q21.11 and 8q24.3. A novel amplicon was identified at 5p15.33. Frequent losses were found at 1p36.22, 8q23.3, 11p13, 11q23, and 22q13. Over 130 genes were identified with concurrent increases or decreases in expression that mapped to these regions of copy number alterations. LOH analysis revealed three tumors with whole chromosome or p arm allelic loss of chromosome 17. Genes were identified that mapped to copy neutral LOH regions. LOH with accompanying copy loss was detected on Xp24 and Xp25 and genes mapping to these regions with decreased expression were identified. Gene expression data highlighted the PPARα/RXRα Activation Pathway as down-regulated in the tumor samples.
conclusionWe have demonstrated the utility of the application of integrated analysis using high resolution CGH and whole genome transcript analysis for detecting driver genes in IDC. The high resolution platform allowed a refined demarcation of CNAs and gene expression profiling provided a mechanism to detect genes directly impacted by the CNA. This is the first report of LOH integrated with gene expression in IDC using a high resolution platform.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.